-
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
25 Aug 2023 05:20 GMT
… ; -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its … of patients." About 3SBio Inc. 3SBio is a leading bio-pharmaceutical … therapeutic areas such as nephrology, oncology, autoimmune diseases, ophthalmology and dermatology …
-
Oncology Partnering 2016-2023: Insights Into Trends, Players, and Financials for Over 6,000 Deal Records - ResearchAndMarkets.com
23 Jun 2023 13:41 GMT
… leading healthcare companies.
Trends in oncology dealmaking in the biopharma industry … terms companies are currently entering oncology deals.
The report presents … bio
2X Oncology
3B Pharmaceuticals
3D Medicines
3P Biopharmaceuticals
3SBio
4baseCare
4C …
-
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
22 Mar 2023 04:45 GMT
… medium and chromatography filling . 3SBio will focus on providing proprietary … standard drugs."
About 3SBio Inc.
3SBio is a leading bio-pharmaceutical … therapeutic areas such as nephrology, oncology, autoimmune diseases, ophthalmology and dermatology …
-
Allorion Therapeutics, a next-generation precision medicine company focusing on oncology and autoimmune diseases, raises $50 million Series B financing
10 Mar 2023 06:03 GMT
… next-generation precision medicine for oncology and autoimmune diseases, announces the … Capital, Long River Investment (LRI), 3SBio, Octagon Capital, and Elikon Venture … next-generation precision medicine for oncology and autoimmune diseases. With highly …
-
Global Oncology Partnering 2017-2022: Deal Trends, Players and Financials - ResearchAndMarkets.com
28 Jun 2022 12:46 GMT
… healthcare companies.
Trends in Oncology partnering deals
Financial deal … stage of development
Oncology partnering agreement structure
Oncology partnering contract documents …
2X Oncology
3B Pharmaceuticals
3D Medicines
3P Biopharmaceuticals
3SBio
4baseCare
…
-
Global Biosimilars Partnering Terms and Agreements 2010 to 2022: Featuring Boston Oncology, Concord Biosciences, Horizon 2020 & More - ResearchAndMarkets.com
24 Jun 2022 13:13 GMT
… by technology type
Companies Mentioned
3SBio
180 Life Sciences
Abbvie
Abreos …
Boehringer Ingelheim
Bolt Biotherapeutics
Boston Oncology
Bruker
C-Bridge Capital
Catalent …
-
Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell Engager NM28
14 Dec 2021 08:30 GMT
… Therapeutics AG (Numab) and 3SBio Inc. (“3SBio”, HKEX:1530) announced today … Therapeutics
Numab Therapeutics is an oncology-focused biopharmaceutical company based … in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology. 3SBio is …
-
TLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in China
26 Aug 2020 09:40 GMT
… and scalable in manufacturing. About 3SBio 3SBio is a fully-integrated biotechnology … in oncology, auto-immune diseases, nephrology, metabolic diseases and dermatology. 3SBio is … 30 product candidates under development. 3SBio's manufacturing capabilities …
-
Global Oncology Partnering 2014-2020: Deal Trends, Players and Financials - ResearchAndMarkets.com
14 May 2020 14:45 GMT
… , development and commercialization of Oncology technologies and products.
Analyzing … Oncology
3B Pharmaceuticals
3DMed
3D Signatures
3M Drug Delivery Systems
3PrimeDx
3SBio …
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH ONCOLOGY
SOURCE: Research and Markets
…
-
Oncology Partnering Insights, 2014-2019: Worldwide Deal Trends, Players and Financials
28 Jan 2020 10:54 GMT
… of development
Oncology partnering agreement structure
Oncology partnering contract … development and commercialization of Oncology technologies and products.
… Oncology
3B Pharmaceuticals
3DMed
3D Signatures
3M Drug Delivery Systems
3PrimeDx
3SBio …
About
© 1995-2025